Prevalence, severity, and predictors of dry eye and dry mouth in Chinese patients with primary Sjögren syndrome
- 206 Downloads
Dry eye and dry mouth are typical clinical symptoms of primary Sjögren’s syndrome (pSS), yet not considered in the assessment of severity and predictors in China. This study aimed to investigate the prevalence, severity, and potential predictors of dry eye/dry mouth among Chinese pSS patients. A cross-sectional study was conducted from the Affiliated Hospital of Nantong University. A series of questionnaires were applied: Ocular Surface Disease Index (OSDI), EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI)-dry mouth items, fatigue severity scale (FSS), the 10 cm visual analog scale (VAS). Laboratory examinations were taken to obtain some biochemical indicators (i.e., C-reactive protein, erythrocyte sedimentation rate, anti-SSA/SSB antibody). Stepwise logistic/linear regression model was used to investigate the potential predictors of dry eye/dry mouth, respectively. Statistical analysis was performed using SPSS version 20.0. Two hundred twenty-four pSS patients were included in this study. Among them, 215 (95.98%) patients reported ESSPRI-dry mouth items score > 0, and the mean score was 4.92 ± 2.43. In addition, according to the score of OSDI, 84 (37.5%) subjects reported non-dry eye, whereas 140 (62.5%) subjects reported dry eye (44 mild, 31 moderate, 65 severe), and the mean of the total OSDI score was 25.01 ± 23.58. Then, using logistic regression and linear regression respectively, we found that age and fatigue were the potential predictors of dry eye, whereas dry mouth was predicted by age, fatigue, total pain, and ESR. The results of this study suggested that rheumatologists should pay attention to pSS patients’ dry eye and dry mouth, especially those with older age, higher level of ESR, more severe fatigue, and pain.
KeywordsChina Dry eye Dry mouth Predictors Primary Sjögren syndrome
The authors would like to thank Jing Li, Genkai Guo, and Yunfei Xia for their valuable help in patient recruitment and data extraction as well as all patients who participated in the study.
This study was supported by National Natural Science Foundation of China (Grant No. 81671616 and 81471603); Science and technology Project of Nantong City (Grant No. MS32015021 and MS22015064 and MS22016028); the project of “333 Natural Science Foundation” of Jiangsu (Grant No. BRA2016527).
Compliance with ethical standards
All procedures performed in this study were in accordance with the ethical standards of the institutional research committee (approval number 2017-K003).
- 3.Zhang Q, Wang X, Chen H, Shen B (2017) Sjögren’s syndrome is associated with negatively variable impacts on domains of health related quality of life: evidence from short form 36 questionnaire and meta-analysis. Patient Prefer Adherence 11:905–911. https://doi.org/10.2147/PPA.S132751 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Arakaki R, Eguchi H, Yamada A, Kudo Y, Iwasa A, Enkhmaa T, Hotta F, Mitamura-Aizawa S, Mitamura Y, Hayashi Y, Ishimaru N (2014) Anti-inflammatory effects of rebamipide eyedrop administration on ocular lesions in a murine model of primary Sjögren’s syndrome. PLoS One 9:e98390. https://doi.org/10.1371/journal.pone.0098390 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Crincoli V, Di Comite M, Guerrieri M, Rotolo RP, Limongelli L, Tempesta A, Iannone F, Rinaldi A, Lapadula G, Favia G (2018) Orofacial manifestations and temporomandibular disorders of Sjögren syndrome: an observational study. Int J Med Sci 15:475–483. https://doi.org/10.7150/ijms.23044 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Vitali C, Mariette X, Asmussen K, Jacobsen S, Bartoloni E, Gerli R, Bijlsma JW, Kruize AA, Bombardieri S, Bookman A, Kallenberg C, Meiners P, Brun JG, Jonsson R, Caporali R, Carsons S, De Vita S, Del Papa N, Devauchelle V, Saraux A, Fauchais AL, Sibilia J, Hachulla E, Illei G, Isenberg D, Jones A, Manoussakis M, Mandl T, Jacobsson L, Demoulins F, Montecucco C, Ng WF, Nishiyama S, Omdal R, Parke A, Praprotnik S, Tomsic M, Price E, Scofield H, L Sivils K, Smolen J, Laqué RS, Steinfeld S, Sutcliffe N, Sumida T, Valesini G, Valim V, Vivino FB, Vollenweider C (2015) EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open 1:e000022. https://doi.org/10.1136/rmdopen-2014-000022 CrossRefPubMedCentralGoogle Scholar
- 19.Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E, Brun JG, Kruize AA, Praprotnik S, Tomsic M, Gottenberg JE, Devauchelle V, Devita S, Vollenweider C, Mandl T, Tzioufas A, Carsons S, Saraux A, Sutcliffe N, Vitali C, Bowman SJ, Sjögren's Task Force EULAR (2011) EULAR Sjogren’s syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis 70:968–972. https://doi.org/10.1136/ard.2010.143743 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Bezzina OM, Gallagher P, Mitchell S, Bowman SJ, Griffiths B, Hindmarsh V, Hargreaves B, Price EJ, Pease CT, Emery P, Lanyon P, Bombardieri M, Sutcliffe N, Pitzalis C, Hunter J, Gupta M, McLaren J, Cooper AM, Regan M, Giles IP, Isenberg DA, Saravanan V, Coady D, Dasgupta B, McHugh NJ, Young-Min SA, Moots RJ, Gendi N, Akil M, MacKay K, Ng WF, Robinson LJ, Primary Sjögren's Syndrome Registry UK (2017) Subjective and objective measures of dryness symptoms in primary Sjögren’s syndrome: capturing the discrepancy. Arthritis Care Res (Hoboken) 69:1714–1723. https://doi.org/10.1002/acr.23165 CrossRefGoogle Scholar
- 26.Morcillo C, Brito-Zerón P, García-Sánchez I, Gheitasi H, Bové A, Ramos-Casals M, Horvath IF, Sivils K, Scofield H, Mariette X, Mandl T, Li X, Sandhya P, Corazza L, De Vita S, Sánchez-Guerrero J, van der Heijden E, Wahren-Herlenius M, Bartoloni E, Downie-Doyle S, Park SH, Kawano M, Carubbi F, Saraux A, Astorri E, Vissink A, Hammenfors D, Khalil HM, Morel J, Vollenveider C, Atzeni F, Retamozo S, Trevisano VM, Kostov B, Sisó-Almirall A, Sibilia J, Miceli-Richard C, Nocturne G, Benessiano J, Dieude P, Dubost JJ, Fauchais AL, Goeb V, Hachulla E, Larroche C, Le Guern V, Puéchal X, Morel J, Perdriger A, Rist S, Vittecoq O, Ravaud P, Díaz-López B, Casanovas A, Pallarés L, López-Dupla M, Pérez-Alvarez R, Ripoll M, Pinilla B, Akasbi M, Maure B, Fonseca E, Canora J, de la Red G, Chamorro AJ, Jiménez-Heredia I, Fanlo P, Guisado-Vasco P, Zamora M (2017) Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the big data Sjögren project consortium. Ann Rheum Dis 76:1042–1050. https://doi.org/10.1136/annrheumdis-2016-209952 CrossRefGoogle Scholar
- 29.Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Yves Hatron P, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Saliou P, Pers JO, Seror R, Saraux A (2017) Severe health-related quality of life impairment in active primary Sjögren’s syndrome and patient-reported outcomes: data from a large therapeutic trial. Arthritis Care Res (Hoboken) 69:528–535. https://doi.org/10.1002/acr.22974 CrossRefGoogle Scholar
- 36.Azuma N, Katada Y, Kitano S, Sekiguchi M, Kitano M, Nishioka A, Hashimoto N, Matsui K, Iwasaki T, Sano H (2015) Rapid decrease in salivary epidermal growth factor levels in patients with Sjögren’s syndrome: a 3-year follow-up study. Mod Rheumatol 25:876–882. https://doi.org/10.3109/14397595.2015.1034941 CrossRefPubMedPubMedCentralGoogle Scholar